{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:13:46Z","timestamp":1789492426498,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001839","name":"University Grants Committee","doi-asserted-by":"publisher","award":["14109122"],"award-info":[{"award-number":["14109122"]}],"id":[{"id":"10.13039\/501100001839","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:25:06Z","timestamp":1784978706000},"page":"653-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The hepatocellular carcinoma wish list: Five aspirations for future care"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"Stephen L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6417","authenticated-orcid":false,"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.07.001_bib1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.07.001_bib2","article-title":"Hepatocellular carcinoma: epidemiology, diagnosis and treatment","volume":"7","author":"Mauro","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.07.001_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.07.001_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/AIpc2500801","article-title":"Leveraging artificial intelligence in drug and biological product development: an FDA and clinical trial transformation initiative workshop report","volume":"2","author":"Poddar","year":"2025","journal-title":"NEJM AI"},{"key":"10.1016\/j.jhep.2026.07.001_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jhep.2025.08.018","article-title":"New targets and new drugs for hepatobiliary cancers","volume":"84","author":"Chan","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.001_bib6","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/med.22030","article-title":"Elimination of the hepatitis B virus: a goal, a challenge","volume":"44","author":"Ponde","year":"2024","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jhep.2026.07.001_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2026.108849","article-title":"Identifying barriers to Hepatitis C virus elimination in the era of direct-acting antivirals","author":"Talbot","year":"2026","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jhep.2026.07.001_bib8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.cgh.2024.11.012","article-title":"Temporal changes in risk factors of hepatocellular carcinoma in a prospective cirrhosis cohort","volume":"23","author":"Cholankeril","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.001_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.001_bib10","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.07.001_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2026.102225","article-title":"Challenges and adherence to hepatocellular carcinoma surveillance in patients with advanced chronic liver disease","author":"da Silva","year":"2026","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2026.07.001_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis","volume":"77","author":"Singal","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.001_bib13","first-page":"17","article-title":"Revolutionizing oncology through AI: addressing cancer disparities by improving screening, treatment, and survival outcomes via integration of social determinants of health","author":"Srivastav","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2026.07.001_bib14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1021\/acsmedchemlett.2c00130","article-title":"KRAS inhibitors and target engagement technology: from undruggable to druggable targets in cancer Therapeutics","volume":"13","author":"Kargbo","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jhep.2026.07.001_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1158\/0008-5472.CAN-20-3108","article-title":"Drugging the \u201cundruggable\u201d MYCN oncogenic transcription factor: overcoming previous obstacles to impact childhood cancers","volume":"81","author":"Wolpaw","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2026.07.001_bib16","article-title":"Radiological diagnosis of hepatocellular carcinoma does not preclude biopsy before treatment","volume":"6","author":"Brusset","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.07.001_bib17","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41416-021-01535-2","article-title":"Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit","volume":"125","author":"Childs","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2026.07.001_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.001_bib19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO-26-00015","article-title":"Transarterial chemoembolization and immunotherapy: another good marriage?","volume":"44","author":"Chan","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.07.001_bib20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.001_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.001_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.esmogo.2023.08.001","article-title":"Neoadjuvant immunotherapy for early-stage hepatocellular carcinoma: the arts and science","volume":"1","author":"Chan","year":"2023","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.jhep.2026.07.001_bib23","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.jhep.2025.12.001","article-title":"Reply to: \u201cComment on \u201dNivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration","volume":"84","author":"Hsu","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.001_bib24","first-page":"758","article-title":"Current perspectives on perioperative combination therapy for hepatocellular carcinoma","volume":"14","author":"Nishio","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2026.07.001_bib25","first-page":"655","article-title":"Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2026.07.001_bib26","doi-asserted-by":"crossref","DOI":"10.1159\/000549955","article-title":"Early safety results from the phase 3b SIERRA study of durvalumab and tremelimumab as first-line treatment for participants with unresectable hepatocellular carcinoma and a poor prognosis","author":"Chan","year":"2025","journal-title":"Liver Cancer"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826027054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826027054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:53:42Z","timestamp":1789491222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826027054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0168827826027054"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.07.001","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The hepatocellular carcinoma wish list: Five aspirations for future care","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}